Clinical trial
A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
NCT07904507 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, Phase 4, 266 participants (estimated). Lead sponsor University Hospital, Basel, Switzerland; Switzerland. Primary measure: Atrial-Fibrillation-related Quality of Life.
How it compares
345 similar trials: same condition (Atrial Fibrillation) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
- Official title
- BRACE-AFib: Beta-blocker Replacement and Calcium Channel Blockers Evaluation in Atrial Fibrillation
- Lead sponsor
- University Hospital, Basel, Switzerland
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- October 31, 2029
- Enrollment
- 266 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Arrhythmias, Cardiac, Atrial Fibrillation
Registry terms: atrial fibrillation (af)
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- Switzerland
- Lead sponsor
- University Hospital, Basel, Switzerland
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Diltiazem | Experimental | Experimental intervention |
Show registry wording133 patients are randomized to the experimental intervention and treated with the non-dihydropyridine calcium channel blocker (NDCC) Diltiazem. | ||
| Bisoprolol | Active comparator | Control Intervention |
Show registry wording133 patients are randomized to the control arm and treated with the beta-blocker Bisoprolol. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Atrial-Fibrillation-related Quality of Life | From baseline to 3 months |
Show registry wordingChange in Atrial-Fibrillation-related Quality of Life between Non-dihydropyridine calcium channel blockers (NDCC) versus continuation of beta-blockers (BB) from baseline to 3 months in patients with Atrial-Fibrillation. The primary outcome uses the AFEQT questionnaire: The AFEQT 20-item questionnaire is a validated, AF-specific QoL tool. It assesses 4 domains: symptoms, daily activities, treatment concerns, and treatment satisfaction. The overall AFEQT score is calculated using the first 3 domains and ranges from 0 = worst to 100 = best QoL. Additionally, for each domain of interest, there is a corresponding subscale score: symptoms, daily activities, treatment concerns, and treatment satisfaction subscale scores. Each subscale ranges from 0 = worst to 100 = best QoL and is scored separately. The AFEQT questionnaire will be done at baseline before the intake of the first study drug and after three months of intervention. | |
Lead sponsor's other trials
University Hospital, Basel, Switzerland, most recent start first.
+984 more trials
Similar trials
Same condition (Atrial Fibrillation) and phase, most recent start first.
+340 more trials See the condition page